U.S. markets closed

Perrigo Company plc (PRGO)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
46.57-0.62 (-1.31%)
At close: 4:00PM EDT
46.57 0.00 (0.00%)
After hours: 04:39PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close47.19
Open47.00
Bid46.62 x 800
Ask46.55 x 800
Day's Range46.31 - 47.12
52 Week Range38.20 - 58.83
Volume842,652
Avg. Volume1,065,690
Market Cap6.219B
Beta (5Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-1.71
Earnings DateAug 03, 2021 - Aug 09, 2021
Forward Dividend & Yield0.96 (2.07%)
Ex-Dividend DateJun 03, 2021
1y Target Est54.13
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-29% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Reuters

    UPDATE 1-U.S. Supreme Court rebuffs AbbVie appeal in patent fight involving AndroGel drug

    The U.S. Supreme Court on Monday declined to hear AbbVie Inc's challenge to a lower court's decision that it violated federal antitrust law by pursuing a "sham" patent complaint against rival Perrigo Co over AbbVie's blockbuster testosterone replacement drug AndroGel. The justices turned away AbbVie's appeal and left intact the lower court's finding that its 2011 complaint against Perrigo was brought solely to delay Perrigo's proposed generic version of AndroGel. The Philadelphia-based 3rd U.S. Circuit Court of Appeals last year threw out a federal judge's order requiring AbbVie and partner Besins Pharmaceuticals to disgorge $448 million in profits to the Federal Trade Commission, but found that the judge had correctly determined that they had violated antitrust law.

  • Why Drugmaker Perrigo Could Surprise on the Upside
    TheStreet.com

    Why Drugmaker Perrigo Could Surprise on the Upside

    We last reviewed the charts of Perrigo Corp. on April 9, 2020. In the daily bar chart of PRGO, below, we can see that the shares broke a downtrend line and have rallied above the 50-day and 200-day moving average lines. The daily On-Balance-Volume (OBV) line has been moving higher the past three months to support and confirm the price gains.

  • Perrigo (PRGO) Up 2.9% Since Last Earnings Report: Can It Continue?
    Zacks

    Perrigo (PRGO) Up 2.9% Since Last Earnings Report: Can It Continue?

    Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.